Hidradenitis Suppurativa Market to Showcase Remarkable Growth at a CAGR of 12.4% by 2034 | DelveInsight
November 20, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Hidradenitis Suppurativa Market to Showcase Remarkable Growth at a CAGR of 12.4% by 2034 | DelveInsight According to DelveInsight’s analysis, the...
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
November 07, 2024 07:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable...
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024 07:30 ET
|
InflaRx N.V.
Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I)Initiation of...
InflaRx Hosts R&D Event Highlighting the Promise of INF904
June 05, 2024 12:00 ET
|
InflaRx N.V.
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential...
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
April 10, 2024 07:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions MoonLake to tap into Komodo’s technology and...
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie's Humira
January 10, 2024 15:58 ET
|
Spherix Global Insights
Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as...
ROSEN, A RESPECTED AND LEADING FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN
December 16, 2023 10:11 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 16, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and...
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN
November 30, 2023 13:04 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and...
SLRN NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN
November 24, 2023 11:24 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NYSE: SLRN) between May 4, 2023 and September...
ROSEN, A LEADING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN
November 18, 2023 13:16 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 18, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...